Molecular Partners Analyst Ratings
Molecular Partners Analyst Ratings
While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a downgraded with a price target of $30.00 to $8.00. The current price Molecular Partners (MOLN) is trading at is $6.25, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2022 | 28% | SVB Leerink | $30 → $8 | Downgrades | Outperform → Market Perform |
| 05/25/2022 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 04/27/2022 | 364% | SVB Leerink | $42 → $29 | Maintains | Outperform |
| 01/14/2022 | 572% | SVB Leerink | $35 → $42 | Maintains | Outperform |
| 08/27/2021 | 460% | SVB Leerink | $36 → $35 | Maintains | Outperform |
| 07/13/2021 | 700% | Cowen & Co. | → $50 | Initiates Coverage On | → Outperform |
| 06/21/2021 | 300% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/29/2022 | 28% | SVB Leerink | 30 美元 → 8 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 05/25/2022 | — | 瑞士信贷 | 升级 | 表现不佳 → 中性 | |
| 04/27/2022 | 364% | SVB Leerink | 42 美元 → 29 美元 | 维护 | 跑赢大盘 |
| 2022 年 1 月 14 日 | 572% | SVB Leerink | 35 美元 → 42 美元 | 维护 | 跑赢大盘 |
| 08/27/2021 | 460% | SVB Leerink | 36 美元 → 35 美元 | 维护 | 跑赢大盘 |
| 2021 年 7 月 13 日 | 700% | Cowen & Co. | → 50 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 06/21/2021 | 300% | HC Wainwright & Co. | → 25 美元 | 假设 | → 购买 |
Molecular Partners Questions & Answers
分子合作伙伴问题与解答
The latest price target for Molecular Partners (NASDAQ: MOLN) was reported by SVB Leerink on August 29, 2022. The analyst firm set a price target for $8.00 expecting MOLN to rise to within 12 months (a possible 28.00% upside). 4 analyst firms have reported ratings in the last year.
SVB Leerink于2022年8月29日公布了分子合作伙伴（纳斯达克股票代码：MOLN）的最新目标股价。该分析公司将目标股价定为8.00美元，预计MOLN将在12个月内升至12个月（可能上涨28.00％）。去年有4家分析公司公布了评级。
The latest analyst rating for Molecular Partners (NASDAQ: MOLN) was provided by SVB Leerink, and Molecular Partners downgraded their market perform rating.
Molecular Partners（纳斯达克股票代码：MOLN）的最新分析师评级由SVB Leerink提供，Molecular Partners下调了其市场表现评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Partners was filed on August 29, 2022 so you should expect the next rating to be made available sometime around August 29, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Molecular Partners的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。分子合作伙伴的最新评级是在2022年8月29日发布的，因此您应该预计下一个评级将在2023年8月29日左右公布。
While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a downgraded with a price target of $30.00 to $8.00. The current price Molecular Partners (MOLN) is trading at is $6.25, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的分子合作伙伴（MOLN）评级已下调，目标股价为30.00美元至8.00美元。Molecular Partners（MOLN）目前的交易价格为6.25美元，超出了分析师的预期区间。
